NZ503551A - PDE4 inhibitors for the treatment of inflammatory skin diseases - Google Patents

PDE4 inhibitors for the treatment of inflammatory skin diseases

Info

Publication number
NZ503551A
NZ503551A NZ503551A NZ50355198A NZ503551A NZ 503551 A NZ503551 A NZ 503551A NZ 503551 A NZ503551 A NZ 503551A NZ 50355198 A NZ50355198 A NZ 50355198A NZ 503551 A NZ503551 A NZ 503551A
Authority
NZ
New Zealand
Prior art keywords
xanthine
use according
compound
cyclopropylmethyl
butyl
Prior art date
Application number
NZ503551A
Other languages
English (en)
Inventor
Don E Griswold
Siegfried Benjamin Christensen
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NZ503551A publication Critical patent/NZ503551A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ503551A 1997-10-17 1998-10-16 PDE4 inhibitors for the treatment of inflammatory skin diseases NZ503551A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6374697P 1997-10-17 1997-10-17
PCT/US1998/021886 WO1999020280A1 (en) 1997-10-17 1998-10-16 Novel use of compounds for anti-pruritic activity

Publications (1)

Publication Number Publication Date
NZ503551A true NZ503551A (en) 2002-05-31

Family

ID=22051225

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ503551A NZ503551A (en) 1997-10-17 1998-10-16 PDE4 inhibitors for the treatment of inflammatory skin diseases

Country Status (18)

Country Link
EP (1) EP1030666A4 (tr)
JP (1) JP2001520196A (tr)
KR (1) KR20010031149A (tr)
CN (1) CN1306426A (tr)
AR (1) AR015966A1 (tr)
AU (1) AU740875B2 (tr)
BR (1) BR9814080A (tr)
CA (1) CA2306985A1 (tr)
CO (1) CO4810374A1 (tr)
CZ (1) CZ20001376A3 (tr)
HU (1) HUP0003792A3 (tr)
IL (1) IL135581A0 (tr)
NO (1) NO20001847L (tr)
NZ (1) NZ503551A (tr)
PL (1) PL341062A1 (tr)
TR (1) TR200001040T2 (tr)
WO (1) WO1999020280A1 (tr)
ZA (1) ZA989450B (tr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250518B2 (en) 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
MXPA03006885A (es) 2001-01-31 2003-11-13 Pfizer Prod Inc Derivados de eteres utiles como agentes inhibidores de las isozimas pde4.
BR0116852A (pt) 2001-01-31 2004-02-25 Pfizer Prod Inc Derivados biarilados de nicotinamida úteis como inibidores de isozimas pde4
PL365443A1 (en) 2001-01-31 2005-01-10 Pfizer Products Inc. Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes
US20030175314A1 (en) * 2001-11-19 2003-09-18 Didriksen Erik Johannes Pharmaceutical composition for dermal application
WO2005007161A1 (ja) * 2003-07-17 2005-01-27 Santen Pharmaceutical Co., Ltd. ピペリジン誘導体を有効成分とする掻痒治療剤
WO2005053672A1 (ja) * 2003-12-04 2005-06-16 Santen Pharmaceutical Co., Ltd. シロミラストまたはその塩を有効成分とする掻痒治療剤
JP2005187458A (ja) * 2003-12-04 2005-07-14 Santen Pharmaceut Co Ltd シロミラストまたはその塩を有効成分とする掻痒治療剤
WO2005077950A2 (en) * 2004-02-14 2005-08-25 Smithkline Beecham Corporation Medicaments with hm74a receptor activity
JP2008137892A (ja) * 2005-03-04 2008-06-19 Eisai Co Ltd 止痒剤
WO2007017262A1 (en) 2005-08-10 2007-02-15 Smithkline Beecham Corporation Xanthine derivatives as selective hm74a agonists
TWI404709B (zh) * 2006-02-21 2013-08-11 Eisai R&D Man Co Ltd 4- (3-benzamidophenyl) -6,7-dimethoxy-2-methylamine quinazoline derivatives
CA2637573C (en) * 2006-02-21 2013-07-02 Eisai R&D Management Co., Ltd. 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivatives
AU2008215411B2 (en) 2007-02-16 2012-11-22 Eisai R & D Management Co., Ltd. Crystal, amorphous form and salt of methyl N-[3-(6,7-dimethoxy- 2-methylaminoquinazolin-4-yl)phenyl]terephthalamic acid
WO2009025239A1 (ja) 2007-08-17 2009-02-26 Eisai R & D Management Co., Ltd. 新規外用剤
ATE538102T1 (de) 2007-08-17 2012-01-15 Eisai R&D Man Co Ltd Verfahren zur herstellung eines chinazolinderivats
JP5985475B2 (ja) * 2011-06-28 2016-09-06 田辺三菱製薬株式会社 新規医薬組成物
BR112017016065A2 (pt) 2015-01-30 2018-04-03 Shanton Pharma Co., Ltd. prevenção ou tratamento de ácido úrico ou doença gotosa

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69132291T2 (de) * 1990-12-21 2000-12-14 Beecham Group P.L.C., Brentford Xanthinderivate
PT889886E (pt) * 1996-03-26 2003-02-28 Altana Pharma Ag Novas fenantridinas substituidas na posicao 6
WO1997043288A1 (en) * 1996-05-15 1997-11-20 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel imidazopyridines
PT968211E (pt) * 1997-03-07 2004-01-30 Altana Pharma Ag Derivados de tetrazoles
CA2282845A1 (en) * 1997-03-18 1998-09-24 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
DK0988302T3 (da) * 1997-06-03 2003-06-02 Altana Pharma Ag Benzonaphthyridiner

Also Published As

Publication number Publication date
WO1999020280A1 (en) 1999-04-29
HUP0003792A2 (hu) 2001-10-28
AR015966A1 (es) 2001-05-30
CN1306426A (zh) 2001-08-01
CZ20001376A3 (cs) 2002-06-12
AU740875B2 (en) 2001-11-15
KR20010031149A (ko) 2001-04-16
HUP0003792A3 (en) 2001-12-28
EP1030666A1 (en) 2000-08-30
PL341062A1 (en) 2001-03-26
IL135581A0 (en) 2001-05-20
CO4810374A1 (es) 1999-06-30
BR9814080A (pt) 2000-09-26
CA2306985A1 (en) 1999-04-29
ZA989450B (en) 1999-04-19
TR200001040T2 (tr) 2001-01-22
JP2001520196A (ja) 2001-10-30
EP1030666A4 (en) 2002-10-16
NO20001847D0 (no) 2000-04-10
NO20001847L (no) 2000-04-10
AU1093899A (en) 1999-05-10

Similar Documents

Publication Publication Date Title
AU740875B2 (en) Novel use of compounds for anti-pruritic activity
JPWO2006041121A1 (ja) 慢性皮膚疾患の治療および／または予防剤
WO2008025543A1 (en) Pharmaceutical compositions for the treatment of fungal infections
WO2008091704A2 (en) Treatment of cushing's syndrome and autism
US6498173B1 (en) Synergistic combination comprising roflumilast and a pde-3 inhibitor
JPS62185014A (ja) 複合調剤薬
CA2136977A1 (en) _-8-tetrahydro-cannabinol as antiemetic
JPH02160720A (ja) 医薬組成物
AU3578289A (en) Certain paf antagonist antihistamine combinations and methods
JP3276762B2 (ja) イソキノリン誘導体を含有する医薬組成物
MXPA00003775A (en) Novel use of compounds for anti-pruritic activity
AU763275B2 (en) Viral treatment
ES2378374T3 (es) Inhibidores de la PDE 4 para el tratamiento de la cistitis intersticial
JPH03215435A (ja) アルドース還元酵素阻害剤を主成分とする潰瘍治療剤
AU592851B2 (en) Transdermal formulations
US5981538A (en) Methods of treating psoriasis employing substituted azaspiranes
JPS6245525A (ja) 脂質低下剤
EP0338010B1 (en) Pharmaceutical compositions for treatment of hyperproliferate skin disease
GB1588095A (en) Composition for the treatment of scabies
US20060079513A1 (en) Methods and compositions including methscopolamine nitrate
AU1563902A (en) Novel use of compounds for anti-pruritic activity
JP2004026810A (ja) 鼻炎用組成物
WO2008002777A2 (en) An anti-viral composition for the topical treatment of herpes labialis (cold sores) and method for use thereof
US20060079514A1 (en) Methods and compositions including methscopolamine bromide
JPH0653678B2 (ja) アレルギ−性疾患治療剤

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)